Katharina Braun1, Youness Ahallal2, Daniel D Sjoberg3, Tarek Ghoneim2, Mario Dominguez Esteban2, John Mulhall4, Andrew Vickers3, James Eastham4, Peter T Scardino4, Karim A Touijer5. 1. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Urology, University Hospital Ruhr University Bochum, Marienhospital Herne, Herne, Germany. 2. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Urology, Weill Medical College of Cornell University, New York, New York. 5. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Urology, Weill Medical College of Cornell University, New York, New York. Electronic address: touijera@mskcc.org.
Abstract
PURPOSE: Active surveillance is becoming an increasingly common management strategy for low grade prostate cancer and involves repeat prostate biopsies over time. It has been hypothesized that serial biopsies can lead to reduced erectile function in patients on active surveillance and we explored this hypothesis in a longitudinally followed cohort. MATERIALS AND METHODS: We identified 342 men on active surveillance whose first biopsy occurred between 2000 and 2009. We investigated erectile function using patient reported outcomes, namely the 6 erectile function questions from the IIEF-6 (International Index of Erectile Function). We estimated the change in erectile function with time using locally weighted scatterplot smoothing. RESULTS: The median (IQR) patient age in this cohort was 64 years (58-68). Median followup on active surveillance was 3.5 years (2.3-5.0) and the median number of biopsies was 5 (3-6). During the first 4 years on active surveillance erectile function decreased 1.0 point per year (95% CI 0.2, 1.7) on the IIEF-6 (scale 1 to 30). When stratified by comorbidities or number of biopsies we see an almost identical decrease in erectile function with time. The use of phosphodiesterase-5 inhibitors increased from 5% to 27% from baseline to year 5 on active surveillance. CONCLUSIONS: In this longitudinally followed active surveillance cohort we observed a small decrease in erectile function and an increase in the use of phosphodiesterase-5 inhibitors with time. While we cannot separate out the effect of multiple biopsies from that of the natural aging process on erectile function in this observational study, our data suggest that active surveillance related biopsies do not have a large impact on erectile function.
PURPOSE: Active surveillance is becoming an increasingly common management strategy for low grade prostate cancer and involves repeat prostate biopsies over time. It has been hypothesized that serial biopsies can lead to reduced erectile function in patients on active surveillance and we explored this hypothesis in a longitudinally followed cohort. MATERIALS AND METHODS: We identified 342 men on active surveillance whose first biopsy occurred between 2000 and 2009. We investigated erectile function using patient reported outcomes, namely the 6 erectile function questions from the IIEF-6 (International Index of Erectile Function). We estimated the change in erectile function with time using locally weighted scatterplot smoothing. RESULTS: The median (IQR) patient age in this cohort was 64 years (58-68). Median followup on active surveillance was 3.5 years (2.3-5.0) and the median number of biopsies was 5 (3-6). During the first 4 years on active surveillance erectile function decreased 1.0 point per year (95% CI 0.2, 1.7) on the IIEF-6 (scale 1 to 30). When stratified by comorbidities or number of biopsies we see an almost identical decrease in erectile function with time. The use of phosphodiesterase-5 inhibitors increased from 5% to 27% from baseline to year 5 on active surveillance. CONCLUSIONS: In this longitudinally followed active surveillance cohort we observed a small decrease in erectile function and an increase in the use of phosphodiesterase-5 inhibitors with time. While we cannot separate out the effect of multiple biopsies from that of the natural aging process on erectile function in this observational study, our data suggest that active surveillance related biopsies do not have a large impact on erectile function.
Authors: Javier Romero-Otero; Borja García-Gómez; José M Duarte-Ojeda; Alfredo Rodríguez-Antolín; Antoni Vilaseca; Sigrid V Carlsson; Karim A Touijer Journal: Int J Urol Date: 2015-11-30 Impact factor: 3.369
Authors: Christopher B Anderson; Amy L Tin; Daniel D Sjoberg; John P Mulhall; Jaspreet Sandhu; Karim Touijer; Vincent P Laudone; James A Eastham; Peter T Scardino; Behfar Ehdaie Journal: BJU Int Date: 2015-07-20 Impact factor: 5.588
Authors: Justin K Lee; Daniel D Sjoberg; Mariam Imnadze Miller; Andrew J Vickers; John P Mulhall; Behfar Ehdaie Journal: Eur Urol Date: 2017-08-26 Impact factor: 20.096
Authors: Shane M Pearce; Chi-Hsiung E Wang; David E Victorson; Brian T Helfand; Kristian R Novakovic; Charles B Brendler; Jeffrey A Albaugh Journal: Sex Med Date: 2015-07-30 Impact factor: 2.491